BioTissue Ocular

BioTissue Ocular We develop innovative Amniotic Membrane products for the management of ocular surface diseases.

BioTissue® is the leader in regenerative biologic therapies and ocular hygiene solutions, helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye.

12/09/2025

Through the generosity of mothers who donate birth tissue and the dedication of physicians.

Together, they’re sharing the miracle of sight.

A big congratulations to Dr. Reena Gupta on presenting her poster at AAO! 👏 Missed the poster floor? You can still catch...
12/08/2025

A big congratulations to Dr. Reena Gupta on presenting her poster at AAO! 👏

Missed the poster floor?
You can still catch her insights! Check out her interview with Ophthalmology360, where she discusses how Cryopreserved Amniotic Membrane after epi-off CXL may help reduce postoperative complications.

Learn more: https://brnw.ch/21wYbGA

Our Chief Commercial Officer, Tom Williamson, shared insights at AAO on how CAM360 AmnioGraft™ is helping physicians int...
12/04/2025

Our Chief Commercial Officer, Tom Williamson, shared insights at AAO on how CAM360 AmnioGraft™ is helping physicians intervene earlier in Dry Eye Disease with a strong focus on patient comfort.

In his interview with Ophthalmology360, he spoke about the growing shift toward earlier intervention and the value of having solutions that make the process easier and more comfortable for patients.

Watch the full interview here: https://brnw.ch/21wY4Ts

12/03/2025

You don’t need months to see progress; you just need the right treatment.

With CAM360 AmnioGraft™, preliminary data has shown it can help patients experience improvements in symptoms in as little as one week.¹



1. Short-Term Outcomes Associated with CAM360 AmnioGraft™ : Results from Real-World Evidence. BioTissue Holdings Inc.; 2025. US-CAM360-0110

CAM360 AmnioGraft™ may help prevent the progression of your Stage 1 Neurotrophic Keratitis patients.  Visit our website ...
12/01/2025

CAM360 AmnioGraft™ may help prevent the progression of your Stage 1 Neurotrophic Keratitis patients.

Visit our website to learn more about CAM360 AG!

On Thanksgiving, we’re reflecting on what truly matters.   🌟 The passion of our people, who bring innovation and care to...
11/27/2025

On Thanksgiving, we’re reflecting on what truly matters.

🌟 The passion of our people, who bring innovation and care to life

👩‍⚕️👨‍⚕️ The trust from providers who choose us to support their patients

💙 The opportunity to make a lasting impact on eye care & beyond

Wishing you a holiday filled with gratitude and joy!

Every breakthrough begins with people willing to challenge the standard of care. At our BioTissue Ocular Summit 2025 in ...
11/20/2025

Every breakthrough begins with people willing to challenge the standard of care.
At our BioTissue Ocular Summit 2025 in Dallas, you — our attendees—brought the ideas, the collaboration, and the momentum that push eye care forward.
We’re honored to keep building with you.

11/19/2025

Your patients have questions. We’ve got answers & resources!

Quick guides, FAQs, and easy-to-follow instructions are just a click away.

👉 https://brnw.ch/21wXE2d

11/14/2025

It’s not just for Dry Eye Disease...CAM360 AmnioGraftᵀᴹ helps you intervene earlier across multiple ocular surface challenges, from mild to moderate Dry Eye to Stage 1 NK.

11/13/2025

💡Not all Amniotic Membranes are processed the same.
Cryopreservation process maintains the innate biological properties, like anti-inflammatory and anti-scarring properties.¹,³

Why settle for less?

1.Cooke, M, Tan, EK, Mandrycky, C. et al.. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014 Oct;23(10):465-74, 476. doi: 10.12968/jowc.2014.23.10.465. PMID: 25296347.

2. Zhang, Y, Helman, A, Mead, O. et al. Processing Methods Affect Biological Properties of Amniotic Membrane Sheet Products. Cornea. 2025;44(6):671-678, June 2025. //DOI: 10.1097/ICO.0000000000003849.

3. Data on file.

11/07/2025

👀 Think NK is “rare?” Think again.
31.4% of Dry Eye patients have been shown to have underlying Neurotrophic Keratitis.¹

Corneal Sensitivity Testing can help you identify NK patients earlier on in your patients.

Don’t let hidden symptoms slip under the radar.



1. Stolz M. The Prevalence of Corneal Sensitivity Loss in Patients with and without Dry Eye Disease. Clin Ophthalmol. 2025 Apr 18;19:1323-1330.

10/30/2025

You didn’t hear it from us… oh wait, yes you did. 👀

Address

7300 Corporate Center Drive, Suite 700
Miami, FL
33126

Alerts

Be the first to know and let us send you an email when BioTissue Ocular posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category